[Skip to Navigation]
Sign In
Invited Commentary
April 18, 2019

Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer: Closing the GAP

Author Affiliations
  • 1Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
JAMA Oncol. 2019;5(6):831-832. doi:10.1001/jamaoncol.2019.0269

Biliary tract cancers (BTCs) are rare gastrointestinal malignant neoplasms, with nearly 6000 cases diagnosed each year in the United States, but outcomes for this group of patients remain grim because BCTs are often discovered late in the disease course. Progress in clinical research has been slow given the limited number of patients, although this pace is changing with improved cooperation among clinicians and new discoveries in therapeutics. Even so, it has been nearly 10 years since the landmark ABC-02 trial,1 which established gemcitabine-cisplatin as the frontline regimen for advanced BTCs. Although gemcitabine-cisplatin has remained the standard of care, median overall survival is reported at just under 1 year. With the advances in systemic treatment that have occurred since 2010, we should do better for patients.

Add or change institution